Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalDiabetes, obesity and metabolism
Volume21
Issue number1
Pages (from-to)84-94
Number of pages11
ISSN1462-8902
DOIs
Publication statusPublished - Jan 2019
MoE publication typeA1 Journal article-refereed

Fields of Science

  • apolipoprotein C3
  • atherogenic dyslipidaemia
  • de novo lipogenesis
  • GLP-1-agonist
  • liraglutide
  • liver fat
  • postprandial lipids
  • remnant lipoproteins
  • FATTY LIVER-DISEASE
  • REMNANT CHOLESTEROL
  • VILDAGLIPTIN THERAPY
  • RECEPTOR AGONISTS
  • TRIGLYCERIDE
  • LIPOPROTEINS
  • METFORMIN
  • EXENATIDE
  • PARTICLES
  • PLACEBO
  • 3121 General medicine, internal medicine and other clinical medicine

Cite this